天賜材料(002709.SZ):擬投資建設年產20萬噸鋰電材料項目
格隆匯8月23日丨天賜材料(002709.SZ)公佈,公司於2021年8月20日召開了第五屆董事會第十七次會議、第五屆監事會第十二次會議,審議通過了《 關於投資建設年產20萬噸鋰電材料項目的議案》,同意公司全資子公司九江天賜高新材料有限公司(“九江天賜”)使用自籌資金投資建設年產20萬噸鋰電材料項目,項目總投資為人民幣 140251.62萬元,其中建設投資為93848.40萬元,鋪底流動資金為46403.22萬元,公司可根據項目實際實施情況,在總投資額度範圍內,對具體的項目投資內容及費用明細進行適當的調整。此次投資建設年產20萬噸鋰電材料項目的事項尚需提交公司股東大會表決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.